Main characteristics of patients at the time of follow-up
| Group A | Group B | |
| Clinical presentation | ||
| Systolic arterial pressure, mm Hg (mean±SD) | 128.1±13.8 | 134±13.8 |
| Diastolic arterial pressure, mm Hg (mean±SD) | 79.7±8.5 | 80.9±9.3 |
| Symptoms/signs of heart failure, n (%) | 2 (3.4) | 2 (6.0) |
| Pharmacological therapy | ||
| ACE inhibitors/ARB, n (%) | 21 (36.2) | 14 (42.4) |
| β-Blockers, n (%) | 24 (41.3) | 12 (36.3) |
| Diuretics, n (%) | 13 (22.4) | 7 (21.2) |
| Calcium antagonists, n (%) | 6 (10.3) | 7 (21.2) |
| Digoxin, n (%) | 3 (5.1) | 11 (33.3)** |
| Anticoagulants, n (%) | 18 (31.0) | 29 (87.8)** |
| Platelet inhibitors, n (%) | 19 (32.7) | 3 (9.0)* |
| Antiarrhythmics | ||
| Amiodarone, n (%) | 10 (17.2) | 1 (3.0) |
| Propafenone, n (%) | 7 (12.0) | 1 (3.0) |
| Flecainide, n (%) | 8 (13.7) | 2 (6.0) |
*p<0.05; **p<0.01.
ARB, angiotensin II receptor blocker.